A-3 Price List_Etcamah-Breast Canc Agt-Estrogen Recptr Antag.xlsx

XLSX spreadsheet 45 KB Posted

Attached to
Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program
Solicitation number
HT9402-26-Q-9404
Issued by

About this file

This is a pricing template for the Department of War (DoW) Pharmacy and Therapeutics (P&T) Committee's November 4-5, 2026 meeting regarding Estrogen Receptor Antagonist breast cancer agents under the Uniform Formulary (UF) program. The template is designed for manufacturers to submit quotes for newly approved drugs (ten drug candidates identified as Newly Approved Drug #1 through #10) for potential inclusion on the TRICARE pharmacy benefit formulary. Quotes are due by October 26, 2026, and manufacturers must submit fully executed signature pages along with the Quote Review Checklist. The pricing template includes multiple appendices for different pricing models: Blanket Purchase Agreement (BPA) pricing with Uniform Formulary and Non-Formulary scenarios at both Military Treatment Facility/Mail Order and TRICARE Retail venues; Additional Discount Program (ADP) pricing using Federal Ceiling Price (FCP) calculations with standard and additional refunds for Tier 2 and Tier 3 formulary categories; and ADP pricing using Wholesale Acquisition Cost (WAC) discount methodologies. Price per unit must remain constant across all package sizes (30s, 100s, 1000s) within each dispensing venue.

The P&T Committee may recommend preferential formulary status (Tier 1 generic treatment) for non-generic agents or complete exclusion from the TRICARE benefit program. Prior Authorization may apply to selected agents, and agents not selected for the RFQ or without submitted quotes may be designated as non-step preferred (after-step). This solicitation falls under the Defense Health Agency's authority to establish the Military Health System pharmacy benefits program as required by 10 U.S.C. § 1074g and implementing regulations in 32 CFR § 199.21. The template itself contains no actual pricing data, indicating it is a blank form awaiting manufacturer submissions for the competitive formulary selection process.

View the file

Other files

Show all 15

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

BPA

UF BPA NDC Price List for the November 2026 DoW P&T Meeting
DoW Uniform Formulary Class:BREAST CANCER AGENTSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:ESTROGEN RECEPTOR ANTAGONISTQuotes due:October 26, 2026
Formulary Notes
Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program.

Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).

Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.

The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.

Blanket Purchase Agreement Appendix – Newly Approved Drug

#1DoW Uniform Formulary Class:BREAST CANCER AGENTSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:ESTROGEN RECEPTOR ANTAGONISTQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1271BCERG1UF1MUniform Formulary1 or moreNO QUOTE
271BCERG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote
Blanket Purchase Agreement Appendix – Newly Approved Drug
#2DoW Uniform Formulary Class:BREAST CANCER AGENTSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:ESTROGEN RECEPTOR ANTAGONISTQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1271BCERG1UF1MUniform Formulary1 or moreNO QUOTE
271BCERG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote
Blanket Purchase Agreement Appendix – Newly Approved Drug
#3DoW Uniform Formulary Class:BREAST CANCER AGENTSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:ESTROGEN RECEPTOR ANTAGONISTQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1271BCERG1UF1MUniform Formulary1 or moreNO QUOTE
271BCERG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#4DoW Uniform Formulary Class:BREAST CANCER AGENTSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:ESTROGEN RECEPTOR ANTAGONISTQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1271BCERG1UF1MUniform Formulary1 or moreNO QUOTE
271BCERG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote
Blanket Purchase Agreement Appendix – Newly Approved Drug
#5DoW Uniform Formulary Class:BREAST CANCER AGENTSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:ESTROGEN RECEPTOR ANTAGONISTQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1271BCERG1UF1MUniform Formulary1 or moreNO QUOTE
271BCERG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#6DoW Uniform Formulary Class:BREAST CANCER AGENTSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:ESTROGEN RECEPTOR ANTAGONISTQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1271BCERG1UF1MUniform Formulary1 or moreNO QUOTE
271BCERG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#7DoW Uniform Formulary Class:BREAST CANCER AGENTSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:ESTROGEN RECEPTOR ANTAGONISTQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1271BCERG1UF1MUniform Formulary1 or moreNO QUOTE
271BCERG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#8DoW Uniform Formulary Class:BREAST CANCER AGENTSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:ESTROGEN RECEPTOR ANTAGONISTQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1271BCERG1UF1MUniform Formulary1 or moreNO QUOTE
271BCERG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote
Blanket Purchase Agreement Appendix – Newly Approved Drug
#9DoW Uniform Formulary Class:BREAST CANCER AGENTSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:ESTROGEN RECEPTOR ANTAGONISTQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1271BCERG1UF1MUniform Formulary1 or moreNO QUOTE
271BCERG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote
Blanket Purchase Agreement Appendix – Newly Approved Drug
#10DoW Uniform Formulary Class:BREAST CANCER AGENTSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:ESTROGEN RECEPTOR ANTAGONISTQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1271BCERG1UF1MUniform Formulary1 or moreNO QUOTE
271BCERG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.

ADP (non-FAMP Discount)

UF ADP Appendix for the November 2026 DoW P&T Meeting
DoW Uniform Formulary Class:BREAST CANCER AGENTSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:ESTROGEN RECEPTOR ANTAGONISTQuotes due:October 26, 2026
Formulary Notes
Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program.

Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).

Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.

* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.

Additional Discount Program Appendix – Newly Approved Drug

#1DoW Uniform Formulary Class:BREAST CANCER AGENTSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:ESTROGEN RECEPTOR ANTAGONISTQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1271BCERG1T21MTier 21 or more
271BCERG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#2DoW Uniform Formulary Class:BREAST CANCER AGENTSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:ESTROGEN RECEPTOR ANTAGONISTQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1271BCERG1T21MTier 21 or more
271BCERG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#3DoW Uniform Formulary Class:BREAST CANCER AGENTSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:ESTROGEN RECEPTOR ANTAGONISTQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1271BCERG1T21MTier 21 or more
271BCERG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#4DoW Uniform Formulary Class:BREAST CANCER AGENTSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:ESTROGEN RECEPTOR ANTAGONISTQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1271BCERG1T21MTier 21 or more
271BCERG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote
Additional Discount Program Appendix – Newly Approved Drug
#5DoW Uniform Formulary Class:BREAST CANCER AGENTSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:ESTROGEN RECEPTOR ANTAGONISTQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1271BCERG1T21MTier 21 or more
271BCERG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#6DoW Uniform Formulary Class:BREAST CANCER AGENTSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:ESTROGEN RECEPTOR ANTAGONISTQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1271BCERG1T21MTier 21 or more
271BCERG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#7DoW Uniform Formulary Class:BREAST CANCER AGENTSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:ESTROGEN RECEPTOR ANTAGONISTQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1271BCERG1T21MTier 21 or more
271BCERG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#8DoW Uniform Formulary Class:BREAST CANCER AGENTSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:ESTROGEN RECEPTOR ANTAGONISTQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1271BCERG1T21MTier 21 or more
271BCERG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#9DoW Uniform Formulary Class:BREAST CANCER AGENTSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:ESTROGEN RECEPTOR ANTAGONISTQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1271BCERG1T21MTier 21 or more
271BCERG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote
Additional Discount Program Appendix – Newly Approved Drug
#10DoW Uniform Formulary Class:BREAST CANCER AGENTSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:ESTROGEN RECEPTOR ANTAGONISTQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1271BCERG1T21MTier 21 or more
271BCERG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.

ADP (WAC Discount)

UF ADP Appendix for the November 2026 DoW P&T Meeting
DoW Uniform Formulary Class:BREAST CANCER AGENTSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:ESTROGEN RECEPTOR ANTAGONISTQuotes due:October 26, 2026
Formulary Notes
Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program.

Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).

Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.

The Wholesale Acquisition Cost (WAC) is obtained from First Databank via daily price updates; it is maintained at the dispensing unit level to five (5) decimal places. If the WAC changes during a calendar quarter, an average WAC will be calculated on a daily weighted basis (per unit only).

WAC is ONLY used for products that do not have a FCP, such as diabetic supplies (i.e., test strips), and can also be applied to covered drugs.

*The quoted WAC Discount percentage will remain static during the life of the agreement.

Additional Discount Program Appendix – Newly Approved Drug

#1DoW Uniform Formulary Class:BREAST CANCER AGENTSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:ESTROGEN RECEPTOR ANTAGONISTQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1271BCERG1T21MTier 21 or more
271BCERG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#2DoW Uniform Formulary Class:BREAST CANCER AGENTSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:ESTROGEN RECEPTOR ANTAGONISTQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1271BCERG1T21MTier 21 or more
271BCERG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#3DoW Uniform Formulary Class:BREAST CANCER AGENTSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:ESTROGEN RECEPTOR ANTAGONISTQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1271BCERG1T21MTier 21 or more
271BCERG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#4DoW Uniform Formulary Class:BREAST CANCER AGENTSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:ESTROGEN RECEPTOR ANTAGONISTQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1271BCERG1T21MTier 21 or more
271BCERG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#5DoW Uniform Formulary Class:BREAST CANCER AGENTSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:ESTROGEN RECEPTOR ANTAGONISTQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1271BCERG1T21MTier 21 or more
271BCERG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#6DoW Uniform Formulary Class:BREAST CANCER AGENTSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:ESTROGEN RECEPTOR ANTAGONISTQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1271BCERG1T21MTier 21 or more
271BCERG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#7DoW Uniform Formulary Class:BREAST CANCER AGENTSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:ESTROGEN RECEPTOR ANTAGONISTQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1271BCERG1T21MTier 21 or more
271BCERG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#8DoW Uniform Formulary Class:BREAST CANCER AGENTSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:ESTROGEN RECEPTOR ANTAGONISTQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1271BCERG1T21MTier 21 or more
271BCERG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#9DoW Uniform Formulary Class:BREAST CANCER AGENTSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:ESTROGEN RECEPTOR ANTAGONISTQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1271BCERG1T21MTier 21 or more
271BCERG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#10DoW Uniform Formulary Class:BREAST CANCER AGENTSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:ESTROGEN RECEPTOR ANTAGONISTQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1271BCERG1T21MTier 21 or more
271BCERG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.

File details come from the government source that posted it. Updated .